This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.
GLP-1 medications and telehealth
GLP-1 receptor agonists are the most effective pharmacological weight-management and glycemic-control tools available in 2026. This hub covers the molecules, the brands, compounded options and how to evaluate providers.
Quick answer
GLP-1 (glucagon-like peptide-1) receptor agonists reduce appetite and improve blood-sugar control. The class includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), plus older and investigational agents. This hub routes you to molecule guides, brand pages, cost analysis and provider reviews.
Regulatory contextCompounded drugs are not FDA-approved: the agency does not review them for safety, effectiveness or quality before they are marketed. Federal law also bars compounding drugs that are essentially a copy of a commercially available approved product — a bar that is lifted only while the drug is on the FDA shortage list. Both shortages are over. The FDA declared the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage resolved on February 21, 2025, and enforcement discretion ended for all compounders between February 18 and May 22, 2025. On April 30, 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list on a finding of no clinical need. Routine compounding of these molecules is therefore no longer lawful on the basis that made the market — a fact most comparison sites still describe as "permanent legitimacy." It is not. The comment period on the 503B proposal closed July 30, 2026, and no final decision had been published as of October 15, 2026. On September 18, 2026 FDA told Empower Pharmacy that compounded tirzepatide and semaglutide products it examined “appear to be essentially copies” of approved drugs (warning letter 738238).
How the dates on this page work. Manufacturer self-pay prices were re-read on 15 October 2026: NovoCare’s Wegovy page and Lilly’s Zepbound savings page. Foundayo prices are carried from LillyDirect pages archived 25 September 2026, because lilly.com blocked automated reads. Figures captured from telehealth provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row or a dated notice says so. We do not restamp a figure we have not re-read.